Strain Data Sheet

RBRC00916

Strain Information

Image
BRC No.RBRC00916
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.Cg-Irf9<tm1Ttg>/TtgRbrc
Former Common nameIRF-9 KO/C57BL/6J ; p48<-/->; IRF-9<-/->, IRF-9 Knockout mouse, C57BL/6J
H-2 Haplotype
ES Cell lineTT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Background strainC57BL/6JJcl
Appearanceblack
Strain developmentDeveloped by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations).
Strain descriptionIRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916).
Colony maintenanceHomozygote x Homozygote
References
Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies.
Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, Kashiwazaki Y, Tarutani M, Tan R S, Takasugi T, Matsuyama T, Mak T W, Noguchi S, Taniguchi T
Genes Cells, 1, 115-124 (1996). 9078371

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Irf9
MGI:107587		interferon regulatory factor 914Irf9<tm1Ttg>
MGI:2446102		targeted mutation 1, Tadatsugu Taniguchi
  • immunodeficiency 65, susceptibility to viral infections(MedGEN)
    • neo neomycin resistance gene (E. coli)14 mouse phosphoglycerate kinase promoter (PGK promoter)

    Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal cytokine secretion(MP:0003009)

  • decreased bone mineral density(MP:0000063)

  • decreased interferon-alpha secretion(MP:0008563)

  • increased susceptibility to viral infection(MP:0002418)
    • Detailed phenotype data

    Ordering Information

    Donor DNAmouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse IRF-9 genomic DNA
    Research applicationImmunology and Inflammation Research
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
    DepositorTadatsugu Taniguchi (The University of Tokyo)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    Lercher A, Cheong JG, Bale MJ, Jiang C, Hoffmann HH, Ashbrook AW, Lewy T, Yin YS, Quirk C, DeGrace EJ, Chiriboga L, Rosenberg BR, Josefowicz SZ, Rice CM.
    Antiviral innate immune memory in alveolar macrophages following SARS-CoV-2 infection ameliorates secondary influenza A virus disease.
    Immunity (2024) 39353439
    Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, Shiota A, Takeshita K, Yasuma-Mitobe K, Riethmacher D, Kaisho T, Norman JM, Mucida D, Suematsu M, Yaguchi T, Bucci V, Inoue T, Kawakami Y, Olle B, Roberts B, Hattori M, Xavier RJ, Atarashi K, Honda K.
    A defined commensal consortium elicits CD8 T cells and anti-cancer immunity.
    Nature 565(7741) 600-605(2019) 30675064
    Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL.
    IRF7-dependent type I interferon production induces lethal immune-mediated disease in STAT1 knockout mice infected with lymphocytic choriomeningitis virus.
    J Virol 88(13) 7578-88(2014) 24760883
    Hofer MJ, Li W, Manders P, Terry R, Lim SL, King NJ, Campbell IL.
    Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus.
    J Virol 86(12) 6932-46(2012) 22496215
    Hofer MJ, Li W, Lim SL, Campbell IL.
    The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9.
    J Neurosci 30(3) 1149-57(2010) 20089923